“White liver” describes a liver that has turned pale, sometimes strikingly so, because its cells have filled with fat. In healthy tissue the liver is a deep reddish-brown; when fat droplets accumulate inside hepatocytes, the organ gradually lightens to a yellowish or creamy white. On an ultrasound screen this fat-laden liver glows unusually bright, which is why radiologists call it a “bright liver” or note “increased echogenicity.” The term shows up in human medicine, in veterinary science (where “white liver disease” is a recognized condition in sheep), and even in the food world when people discuss foie gras. Although the phrase sounds alarming, the underlying problem is almost always some form of hepatic steatosis, and how serious it is depends entirely on what caused it and how far it has progressed.
Why Fat Makes the Liver Turn White
The liver processes virtually all the fat your body absorbs from food, manufactures cholesterol and triglycerides, and packages them for export. When that balance tips, whether because too much fat is arriving, too little is leaving, or the cellular machinery that processes lipids is impaired, triglycerides start piling up inside liver cells. A small amount of intracellular fat is normal. Once fat accounts for more than about five percent of the liver’s weight, the condition crosses into steatosis. At that point the organ’s color begins to shift. A surgeon or pathologist looking at such a liver during a procedure or autopsy would describe it as pale, greasy, and sometimes enlarged. Under a microscope, the cells appear bloated with clear fat vacuoles that push the nucleus to one side.
On ultrasound, those fat-filled cells scatter sound waves differently than normal tissue. The result is a liver that appears brighter than the adjacent kidney, a hallmark sign. A study of patients with mildly abnormal liver enzymes found that about 87 percent of those whose ultrasound showed increased echogenicity had at least moderate steatosis on biopsy, with the technique showing roughly 90 percent sensitivity for picking up fatty change.1PubMed. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases A separate prospective study confirmed that the bright-liver pattern on ultrasound, especially when accompanied by focal areas of lower echogenicity, was a reliable non-invasive marker for fatty infiltration.2PubMed. Hypoechoic lesions in the ‘bright liver’: a reliable indicator of fatty change. A prospective study
The Most Common Cause in Humans
By far the leading reason a person ends up with a white or fatty liver is metabolic dysfunction-associated steatotic liver disease, known as MASLD (and previously called non-alcoholic fatty liver disease, or NAFLD). MASLD is now the most common chronic liver disease worldwide and the leading cause of liver-related illness and death.3PubMed Central. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review It tends to develop alongside the cluster of conditions collectively called metabolic syndrome: excess abdominal weight, high blood sugar, elevated triglycerides, and high blood pressure. Cardiovascular disease, not liver failure, is actually the top killer of people with MASLD, which is why managing heart risk is considered just as important as treating the liver itself.
The name change from NAFLD to MASLD happened in 2023, and you will still see both terms in medical literature and patient handouts. The shift was meant to describe what the disease is (linked to metabolic problems) rather than what it isn’t (not caused by alcohol). In practical terms, the condition is the same: fat in the liver driven by insulin resistance and metabolic dysfunction.
Other Causes of a Fatty, Pale Liver
While MASLD dominates the statistics, several other situations can produce a white liver. Each has a different mechanism, and some are far more urgent.
- Alcohol: Heavy drinking is the classic cause of hepatic steatosis. Alcohol floods the liver with substrates for fat production and simultaneously impairs the export of triglycerides. Even a few weeks of heavy use can produce visible fatty change, which is reversible if drinking stops early enough.
- Drug-induced steatosis: A range of medications can trigger fat accumulation in the liver, including certain corticosteroids, tamoxifen, amiodarone, and some antiretroviral drugs.4PubMed Central. Drug-induced steatohepatitis Even fibrate drugs designed to lower blood triglycerides have been shown in animal models to paradoxically increase fat storage inside liver cells while reducing fat levels in the bloodstream.5PLoS ONE. Peroxisome Proliferator-Activated Receptor α Activation Induces Hepatic Steatosis, Suggesting an Adverse Effect
- Acute fatty liver of pregnancy: This rare but potentially life-threatening complication arises in the third trimester or shortly after delivery. It has been linked to defects in fetal fatty acid metabolism and requires prompt delivery along with supportive care to protect both the mother and baby.6PubMed Central. Acute fatty liver of pregnancy
- Glycogen storage diseases: These inherited metabolic disorders cause abnormal accumulation of glycogen (and sometimes fat) in the liver, often presenting in childhood. The overall incidence is roughly one case per 20,000 to 43,000 live births, and the liver is one of the primary organs affected because it normally stores so much glycogen.7PubMed Central. Glycogen storage diseases: An update
- Ischemic hepatitis: When the liver is suddenly starved of blood flow, typically during shock or severe heart failure, the organ can become pale and swollen. This is a different mechanism from fat accumulation, but the liver may appear pale at imaging or on gross inspection.8International Journal of Medical and Pharmaceutical Case Reports. Hepatic Hypoperfusion in Complex Cardiac Pathology: A Case of Ischemic Hepatitis Secondary to Congenital Heart Disease with HFpEF and Atrial Fibrillation
Symptoms, or the Lack of Them
The frustrating reality of a fatty liver is that most people feel nothing. Early and even moderate steatosis rarely produces specific symptoms, which is why it is so often discovered incidentally during an abdominal ultrasound or blood work ordered for unrelated reasons. When symptoms do appear, they tend to be vague: fatigue, a general sense of heaviness in the upper right abdomen, and sometimes mild discomfort after eating fatty meals.
One underappreciated finding is joint pain. A study comparing patients with fatty liver disease to patients with hepatitis C found that about 65 percent of the fatty liver group reported joint pain, a rate similar to the hepatitis C cohort and higher than researchers expected for a condition typically thought of as “silent.”9SpringerLink / Dig Dis Sci. Musculoskeletal complaints and serum autoantibodies associated with chronic hepatitis C and nonalcoholic fatty liver disease Whether the liver disease directly causes joint inflammation or both share a common driver (like systemic metabolic inflammation) remains an open question, but it is worth knowing that unexplained joint symptoms can accompany fatty liver.
As the disease progresses beyond simple steatosis into steatohepatitis and fibrosis, symptoms become more noticeable. Yellowing of the skin and eyes, itching, swelling in the legs or abdomen, and easy bruising can signal advancing liver damage. By that point, however, the disease has usually been present for years.
How Doctors Diagnose It
Ultrasound remains the first-line tool because it is cheap, widely available, and involves no radiation. When the liver looks brighter than the kidney on a standard abdominal ultrasound, fat is the most likely explanation. The limitation is that ultrasound is qualitative; it tells you fat is there but cannot measure exactly how much.
For more precise measurement, MRI-based proton density fat fraction (MRI-PDFF) is considered the most accurate and reliable method to quantify liver fat.10Gut and Liver. Advanced Imaging Techniques for Assessing Fat, Iron, and Fibrosis in Chronic Liver Disease This technique calculates the proportion of the MRI signal coming from fat molecules versus the total liver signal, giving a direct percentage. Emerging data support MRI-PDFF as a reliable, noninvasive endpoint in clinical trials testing treatments for fatty liver inflammation.11PubMed Central. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials In everyday clinical practice, though, MRI-PDFF is less commonly used simply because of cost and availability. Most people will be diagnosed and monitored with ultrasound and blood tests.
Liver biopsy remains the gold standard when doctors need to determine whether inflammation or scarring has developed alongside the fat. Under the microscope, pathologists look for the hallmarks of steatohepatitis: fat droplets in the cells, clusters of inflammatory cells in the liver lobules, and “ballooning” of damaged hepatocytes. Fibrosis and other changes like lipogranulomas may also be present.12PubMed Central. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis Biopsy is invasive, so it is generally reserved for cases where the degree of damage will change treatment decisions.
What Happens If It Progresses
Simple steatosis on its own is considered relatively benign, but a fraction of people with a fatty liver develop inflammation (steatohepatitis), and from there the disease can march through a well-documented sequence: progressive fibrosis, bridging fibrosis, cirrhosis, and eventually hepatocellular carcinoma.13PubMed Central. Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome Experimental models have mapped out this stepwise progression, showing that steatosis can transition to steatohepatitis within weeks under the right conditions, followed by advancing fibrosis and ultimately cirrhosis.14PubMed Central. Molecular pathogenesis of metabolic dysfunction-associated steatotic liver disease, steatohepatitis, hepatic fibrosis and liver cirrhosis
Not everyone progresses. Estimates vary, but the majority of people with simple fatty liver never develop significant fibrosis, especially if the underlying metabolic risk factors are addressed. The ones at highest risk for progression are those with persistent inflammation (steatohepatitis), diabetes, obesity, and genetic predisposition. That is why identifying steatohepatitis early, either by biopsy or increasingly by non-invasive markers, matters so much for guiding treatment intensity.
The Gut Connection
Research over the past decade has highlighted the gut-liver axis as a driver of fatty liver progression. Your liver receives the majority of its blood supply from the portal vein, which drains directly from the intestines, so it is the first organ exposed to whatever crosses the gut lining. When the gut microbiome is out of balance, a cascade of problems can follow: bacterial overgrowth in the small intestine, damage to the tight-junction proteins that normally seal the intestinal lining, and increased passage of bacterial components like lipopolysaccharide into the portal blood. This low-grade endotoxemia triggers inflammatory signaling in the liver, which can worsen steatosis and push it toward steatohepatitis.15Kosin Medical Journal. Gut microbiota and nonalcoholic fatty liver disease
This connection helps explain why some people with modest amounts of liver fat develop significant inflammation while others with heavier fat loads do not. The state of the gut barrier seems to be one of the variables that tips the balance. It also opens a potential therapeutic avenue: probiotics, dietary fiber, and strategies to restore a healthy microbiome are being studied as adjuncts to standard fatty liver treatment, though no gut-targeted therapy has become standard of care yet.
Treatment Through Lifestyle Changes
For most people with a white or fatty liver, weight loss through diet and exercise is the single most effective intervention. The evidence here is unusually clear and dose-dependent. In a clinical trial of 261 patients with biopsy-proven steatohepatitis, those who lost less than five percent of their body weight over 12 months saw steatohepatitis resolve in only about 10 percent of cases. By contrast, 90 percent of those who lost 10 percent or more of their body weight achieved resolution of steatohepatitis, and 45 percent even saw their fibrosis regress.16PubMed Central. Lifestyle modification in NAFLD/NASH: Facts and figures A separate randomized trial using a low-fat, low-glycemic-index diet with moderate exercise found that 97 percent of participants who lost 10 percent or more of body weight achieved resolution of their fatty liver on MRI.16PubMed Central. Lifestyle modification in NAFLD/NASH: Facts and figures
The catch, of course, is that losing 10 percent of body weight and keeping it off is genuinely difficult. Most real-world patients achieve modest losses in the 3 to 7 percent range, which still provides benefit but does not reliably resolve steatohepatitis. That reality has driven interest in pharmacological options. Still, dietary modification and regular physical activity remain the foundation of management and offer meaningful long-term benefits even when weight loss is moderate.17PubMed Central. Role of diet and lifestyle changes in nonalcoholic fatty liver disease
Medications on the Horizon and in Use
For decades there was no approved drug specifically for fatty liver disease with inflammation. That changed in 2024 when the FDA approved resmetirom (brand name Rezdiffra), a thyroid hormone receptor agonist, for adults with steatohepatitis and moderate to advanced fibrosis. In clinical trials, resmetirom produced the largest reductions in liver fat measured by MRI-PDFF compared to other drug classes, outperforming both FGF21 analogs and GLP-1 receptor agonists in a network meta-analysis.18PubMed Central. Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials
GLP-1 receptor agonists, a class of drugs originally developed for diabetes and now widely used for weight management, have also shown meaningful reductions in liver fat. A systematic review and meta-analysis found that GLP-1 receptor agonists significantly reduced both visceral fat and liver fat content compared to control treatments, with benefits seen in people with type 2 diabetes, fatty liver disease, or both.19PubMed Central. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis Because these drugs also promote weight loss and improve blood sugar control, they address multiple metabolic drivers of fatty liver at once, which makes them especially attractive for patients who have overlapping conditions.
Vitamin E and pioglitazone (a diabetes drug) have been used off-label for years in certain patients with steatohepatitis, though neither has formal FDA approval for that indication. The drug pipeline is busy, with dozens of agents in phase 2 and phase 3 trials targeting different steps of fat accumulation, inflammation, and fibrosis. For now, resmetirom is the only purpose-built option with regulatory approval.
Fatty Liver in Children
Pediatric fatty liver disease is rising in parallel with childhood obesity, and the disease looks somewhat different under the microscope in kids compared to adults. In children, the fat tends to be more heavily deposited and portal-tract inflammation is more prominent, while the lobular inflammation and the specific pattern of scarring around tiny blood vessels (perisinusoidal fibrosis) seen in adults are often milder.12PubMed Central. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis These differences matter because the scoring systems pathologists use to grade severity were designed for adult tissue and may underestimate or misclassify the disease in younger patients.
Treatment in children follows the same principles as in adults: dietary improvements and increased physical activity. There are no approved medications for pediatric fatty liver disease, so lifestyle intervention carries even more weight. Screening is increasingly recommended for children who are overweight or obese, particularly those with a family history of metabolic syndrome or type 2 diabetes.
Ovine White Liver Disease
If you searched “white liver” and came across references to sheep, that is a separate condition with a completely different cause. Ovine white liver disease (OWLD) affects lambs grazing on pastures deficient in cobalt, the trace mineral that gut bacteria need to synthesize vitamin B12. Without adequate B12, fat metabolism in the liver breaks down, and triglycerides accumulate, turning the organ pale, fatty, and fragile.20PubMed Central. Ovine white-liver disease (OWLD). Pathology
Experimentally, lambs fed cobalt-deficient diets developed anorexia, weight loss, tearing eyes, hair loss, and eventually emaciation. Their blood showed low vitamin B12, elevated bilirubin, and increased liver enzymes. At necropsy, the livers had obvious fatty degeneration.21PubMed. Histopathologic and ultrastructural alterations of white liver disease in sheep experimentally depleted of cobalt Field cases in Australia confirmed these findings: affected sheep had consistently low liver cobalt levels and pastures with very low cobalt concentrations. The good news is that the condition responds well to treatment. Cobalt supplementation, either by injection or by placing a slow-release cobalt “bullet” in the rumen, led to clinical improvement, significant weight gain, and recovery of vitamin B12 levels.22PubMed. White liver disease of sheep
OWLD is a useful reminder that fatty liver is not always about overconsumption. In sheep, it is a deficiency disease. The liver turns white not because too much fat is coming in, but because the metabolic machinery needed to process fat properly is starved of an essential cofactor.
Foie Gras and Intentional Steatosis
The most culturally visible example of a deliberately fattened liver is foie gras, produced by force-feeding ducks or geese to induce massive hepatic steatosis. The biology is essentially the same process that causes fatty liver in humans, pushed to an extreme. Transcriptome analysis of overfed geese shows that the liver undergoes wholesale metabolic reprogramming, with major shifts in sugar and fat metabolism pathways, inflammatory responses, and cooperation between peripheral fat tissue and the liver to drive lipid accumulation.23PubMed Central. Multi-omics reveals goose fatty liver formation from metabolic reprogramming The resulting organ can swell to many times its normal size and turn from reddish-brown to a uniform pale yellow.
Waterfowl have some natural adaptations that make them more tolerant of hepatic fat loading than mammals. Migratory species naturally fatten their livers before long flights and then burn that fat during migration without apparent damage. Still, the degree of steatosis induced by commercial gavage far exceeds anything the birds would experience in the wild, and the practice raises ethical questions that have led to bans in several countries. From a purely biological standpoint, though, foie gras is an instructive case study in how quickly and dramatically the liver can change appearance when overwhelmed with lipid.